Session » Systemic Lupus Erythematosus - Clinical Aspects and Treatment II: Patient-Reported Measures, Outcomes and Reporting

Date: Sunday, November 8, 2015

Time: 4:30PM-6:00PM

Meeting: 2015 ACR/ARHP Annual Meeting

Abstract Number: 1063

Admissions and Readmissions of Patients with Systemic Lupus Erythematosus Is a Major Cause of Direct and Indirect Health Care Costs

Abstract Number: 1064

Feasibility and Validity of Patient Reported Outcome Measurement Information System (PROMIS) in SLE

Abstract Number: 1065

Atherosclerotic Vascular Events in a Multinational SLE Inception Cohort: Description and Predictive Risk Factors over a 15 Year Period

Abstract Number: 1066

Temporal Trends and Outcomes of Acute Myocardial Infarction in Systemic Lupus Erythematosus Hospitalizations

Abstract Number: 1067

Sex Differences in Rates of End-Stage Renal Disease and Death Among Medicaid Patients with Incident Lupus Nephritis

Abstract Number: 1068

Assessment of 10-Year Risk of Myocardial Infarction or Stroke in SLE

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under embargo once the ACR has notified presenters of their abstract’s acceptance, and cannot be presented at other meetings after this time. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until November 7 at 10:00 AM ET. Journalists with access to embargoed information also cannot release articles before this time.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Permissions and Reprints

For information about abstract permissions and reprints, see ACR Convergence permissions and reprint policies.